To study the therapeutic effects of Rupixiao tablets and Ruhesanjie tablets to treat breast hyperplasia. Methods： Prospective control randomized control trial was conducted, and 365 patients were divided into two groups. Patients in Rupixiao tablets group were given 2.01g，tid，po, for 3 month and Ruhesanjie tablets group applied 1.44g, tid, po, for 3 month. Patients that are non-respond were included into the other group to continue the treatment. The effect was classified to four degrees, including clinical cure, significantly effective, effective, and ineffective. Follow-up was conducted for half a year. The total effective rates of the two groups were observed. Results： The effective rate (clinical cure, significantly effective, effective) of patients first treated with Rupixiao tablets was 72.22%, and inefficacy rate was 27.78%. The effective rate of Ruhesanjie tablets group was 89.73% and the ineffective rate was 10.27%. Sixty four percent of patients who were not responding to Rupixiao tablets showed effect to Ruhesanjie tablets. While 57.89% of patients had effect with Rupixiao tablets when first treated with Ruhesanjie tablets and showed no effect. Conclusion： Ruhesanjie tablets are a good efficacy medicine to treat breast hyperplasia.